6.00
Plus Therapeutics Inc stock is traded at $6.00, with a volume of 175.79K.
It is down -3.54% in the last 24 hours and up +80.18% over the past month.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
See More
Previous Close:
$6.22
Open:
$6.05
24h Volume:
175.79K
Relative Volume:
0.05
Market Cap:
$41.17M
Revenue:
$5.21M
Net Income/Loss:
$-26.35M
P/E Ratio:
-0.187
EPS:
-32.0862
Net Cash Flow:
$-20.84M
1W Performance:
+7.14%
1M Performance:
+80.18%
6M Performance:
+1,068%
1Y Performance:
+1,100%
Plus Therapeutics Inc Stock (PSTV) Company Profile
Name
Plus Therapeutics Inc
Sector
Industry
Phone
737.255.7194
Address
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
PSTV
Plus Therapeutics Inc
|
6.00 | 42.68M | 5.21M | -26.35M | -20.84M | -32.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
|
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-03-26 | Initiated | Lake Street | Buy |
| Sep-03-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Mar-17-25 | Initiated | D. Boral Capital | Buy |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-20 | Initiated | Maxim Group | Buy |
Plus Therapeutics Inc Stock (PSTV) Latest News
Plus Therapeutics secures FDA orphan drug status for pediatric glioma treatment - MSN
PSTV stock on track for best week since September — here’s what is driving the rally - MSN
PSTV Stock Chart | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - ChartMill
Plus Therapeutics Analyst Ratings and Price Targets | NASDAQ:PSTV - Benzinga
Plus Therapeutics (PSTV) price target decreased by 72.34% to 38.76 - MSN
Plus Therapeutics, Inc. Income Statement – GETTEX:XMP1 - TradingView
Plus Therapeutics regains compliance with Nasdaq - MSN
Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - Yahoo Finance
Plus Therapeutics announces 1-for-25 reverse stock split - MSN
Why is Plus Therapeutics stock gaining Friday? - MSN
symbol__ Stock Quote Price and Forecast - CNN
Plus Therapeutics Inc (PSTV) Stock Price, Quote, News & History - Benzinga
PSTV Should I Buy - Intellectia AI
Plus Therapeutics Initiates Manufacturing Activities, Tech Transfer With SpectronRx - Contract Pharma
Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™ - The Manila Times
Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ - ChartMill
PSTV (PLUS THERAPEUTICS Inc.) reports wider than expected Q4 2025 loss but gains 7.39 percent on optimistic investor outlook.Earnings Surprise - Xã Thanh Hà
Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering - MSN
Plus Therapeutics (PSTV) CDO receives new options and RSU grants - Stock Titan
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Plus Therapeutics Regains Nasdaq Listing Compliance After Reverse Split - The Globe and Mail
PSTV Financials: Income Statement, Balance Sheet & Cash Flow | Plus Therapeutics Inc - Stock Titan
Plus Therapeutics (PSTV) CDO reports no common stock ownership - Stock Titan
Plus Therapeutics | 8-K: Current report - Moomoo
Plus Therapeutics Regains Nasdaq Compliance with Minimum Bid Price Requirement for CNS Cancer Therapies 1 - Minichart
Plus Therapeutics (PSTV) Meets Nasdaq Bid Price Requirement - GuruFocus
Plus Therapeutics regains Nasdaq compliance after one-for-25 reverse split - TradingView
Plus Therapeutics Inc Stock (PSTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):